Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus.

Moberly SP, Mather KJ, Berwick ZC, Owen MK, Goodwill AG, Casalini ED, Hutchins GD, Green MA, Ng Y, Considine RV, Perry KM, Chisholm RL, Tune JD.

Basic Res Cardiol. 2013 Jul;108(4):365. doi: 10.1007/s00395-013-0365-x. Epub 2013 Jun 14.

2.

Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy.

Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen YT, Shannon RP.

Circ Heart Fail. 2010 Jul;3(4):512-21. doi: 10.1161/CIRCHEARTFAILURE.109.900282. Epub 2010 May 13.

3.

Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes.

Asmar M, Højberg PV, Deacon CF, Hare K, Holst JJ, Madsbad S.

Regul Pept. 2010 Feb 25;160(1-3):175-80. doi: 10.1016/j.regpep.2009.12.004. Epub 2010 Jan 13.

PMID:
20005261
4.

Incretin-based therapies, glucometabolic health and endovascular inflammation.

Rizzo M, Nikolic D, Banach M, Patti AM, Montalto G, Rizvi AA.

Curr Pharm Des. 2014;20(31):4953-60. Review.

PMID:
24320037
5.

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.

PMID:
12788877
6.

Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow.

Moberly SP, Berwick ZC, Kohr M, Svendsen M, Mather KJ, Tune JD.

Exp Biol Med (Maywood). 2012 Mar;237(3):334-42. doi: 10.1258/ebm.2011.011288. Epub 2012 Feb 16.

7.

The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.

Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T.

Breast Cancer Res Treat. 2012 Apr;132(2):449-61. doi: 10.1007/s10549-011-1585-0. Epub 2011 Jun 3.

PMID:
21638053
8.

Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism.

Goodwill AG, Tune JD, Noblet JN, Conteh AM, Sassoon D, Casalini ED, Mather KJ.

Basic Res Cardiol. 2014;109(5):426. doi: 10.1007/s00395-014-0426-9. Epub 2014 Jul 9.

9.

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschöp MH.

Sci Transl Med. 2013 Oct 30;5(209):209ra151. doi: 10.1126/scitranslmed.3007218.

10.

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.

Knop FK, Aaboe K, Vilsbøll T, Vølund A, Holst JJ, Krarup T, Madsbad S.

Diabetes Obes Metab. 2012 Jun;14(6):500-10. doi: 10.1111/j.1463-1326.2011.01549.x. Epub 2012 Jan 17.

PMID:
22171657
11.

Altered Plasma Levels of Glucagon, GLP-1 and Glicentin During OGTT in Adolescents With Obesity and Type 2 Diabetes.

Manell H, Staaf J, Manukyan L, Kristinsson H, Cen J, Stenlid R, Ciba I, Forslund A, Bergsten P.

J Clin Endocrinol Metab. 2016 Mar;101(3):1181-9. doi: 10.1210/jc.2015-3885. Epub 2016 Jan 8.

PMID:
26745255
13.

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts.

Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP.

J Pharmacol Exp Ther. 2006 Jun;317(3):1106-13. Epub 2006 Feb 17.

14.

Beta-cell function and mass in type 2 diabetes.

Larsen MO.

Dan Med Bull. 2009 Aug;56(3):153-64.

PMID:
19728971
15.

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.

Egan JM, Meneilly GS, Habener JF, Elahi D.

J Clin Endocrinol Metab. 2002 Aug;87(8):3768-73.

PMID:
12161508
16.
17.

Swim training restores glucagon-like peptide-1 insulinotropic action in pancreatic islets from monosodium glutamate-obese rats.

Svidnicki PV, de Carvalho Leite N, Venturelli AC, Camargo RL, Vicari MR, de Almeida MC, Artoni RF, Nogaroto V, Grassiolli S.

Acta Physiol (Oxf). 2013 Sep;209(1):34-44. doi: 10.1111/apha.12128. Epub 2013 Jul 1.

PMID:
23746147
18.

Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.

Verge D, López X.

Curr Diabetes Rev. 2010 Jul;6(4):191-200. Review.

PMID:
20380625
19.

Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.

Mannucci E, Rotella CM.

Nutr Metab Cardiovasc Dis. 2008 Nov;18(9):639-45. doi: 10.1016/j.numecd.2008.08.002. Epub 2008 Oct 11. Review.

PMID:
18849155
20.

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.

Madsbad S.

Diabetes Obes Metab. 2014 Jan;16(1):9-21. doi: 10.1111/dom.12119. Epub 2013 May 26. Review.

PMID:
23617798

Supplemental Content

Support Center